Cargando…

Extramedullary relapse of IgA-lambda myeloma after recent bortezomib therapy: a case report

Intracranial plasmacytomas are an uncommon presentation of extramedullary relapse of multiple myeloma. The optimal management of extramedullary plasmacytomas remains unclear, with initial reports of bortezomib showing promising clinical results. We describe a case of multiple extracellular, includin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waterhouse, Deirdre F, Moloney, Geraldine A, Gargoum, Fatma S, Hayden, Peter S, O’Gorman, Tom
Formato:	Texto
Lenguaje:	English
Publicado:	Cases Network Ltd 2009
Materias:	Case report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769356/ https://www.ncbi.nlm.nih.gov/pubmed/19918466 http://dx.doi.org/10.4076/1757-1626-2-7456

Ejemplares similares

Bortezomib for Reduction of Proteinuria in IgA Nephropathy
por: Hartono, Choli, et al.
Publicado: (2018)

Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
por: Parrondo, Ricardo D., et al.
Publicado: (2020)

Relapse of Multiple Myeloma Presenting as Extramedullary Plasmacytomas in Multiple Organs
por: Köse, Murat, et al.
Publicado: (2015)

Clinical features of multiple myeloma patients with isolated extramedullary relapse
por: Qu, Xiaoyan, et al.
Publicado: (2018)

Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse
por: Smetana, Jan, et al.
Publicado: (2018)

Relapsing Extramedullary Multiple Myeloma Presenting As Acute Liver Failure
por: Javaid, Hafiza Wajeeha, et al.
Publicado: (2021)

Case Report on Renal Failure Reversal in Lambda Chain Multiple Myeloma with Bortezomib and Dexamethasone
por: Patibandla, Bhanu K., et al.
Publicado: (2014)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma
por: Vincent, L, et al.
Publicado: (2015)

Relapsed Extramedullary Multiple Myeloma Presenting as Bilateral Solid Perirenal Masses
por: Rau, Thomas, et al.
Publicado: (2015)

Relapsed multiple myeloma manifesting as extramedullary plasmacytoma of the breast: Imaging findings
por: Urano, Misugi, et al.
Publicado: (2019)

A rare case of bifocal, extramedullary and hyposecretory relapse of multiple myeloma
por: Minarik, Jiri, et al.
Publicado: (2021)

IgA Nephropathy in a Patient with IgG Myeloma
por: Lakshmi, B. Sangeeta, et al.
Publicado: (2018)

IgA nephropathy in IgG kappa multiple myeloma
por: Couto, Maria Eduarda, et al.
Publicado: (2021)

Lambda Light Chain Non-crystalline Proximal Tubulopathy with IgD Lambda Myeloma
por: Kishi, Seiji, et al.
Publicado: (2018)

A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?
por: Markovic, Uros, et al.
Publicado: (2019)

P894: A PHASE II TRIAL TO EVALUATE THE EFFICACY OF DARATUMUMAB WITH DCEP IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER BORTEZOMIB BASED TREATMENT
por: Byun, J. M., et al.
Publicado: (2022)

A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
por: Lee, Keun-Wook, et al.
Publicado: (2005)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2014)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Clinicopathologic Significance of Predominant Lambda Light Chain Deposition in IgA Nephropathy
por: Ravipati, Prasanth, et al.
Publicado: (2022)

Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients
por: Ting, Kay Reen, et al.
Publicado: (2017)

A Rare Case of Extramedullary Relapse of Multiple Myeloma Causing Bowel Obstruction
por: Bhardwaj, Prarthna V., et al.
Publicado: (2019)

Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma
por: Salmenniemi, Urpu, et al.
Publicado: (2012)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
por: Kumar, S K, et al.
Publicado: (2015)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
por: Cerchione, Claudio, et al.
Publicado: (2016)

Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice
por: Hulin, Cyrille, et al.
Publicado: (2018)

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
por: Mu, Song, et al.
Publicado: (2015)

Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures
por: Dunphy, Katie, et al.
Publicado: (2023)

Complete remission of lambda light chain myeloma presenting with acute renal failure following treatment with bortezomib and steroids
por: Pavan, M., et al.
Publicado: (2010)

Plasmacytoma of the Nasolacrimal Duct Simulating Dacryocystitis: An Uncommon Presentation for Extramedullary Relapse of Multiple Myeloma
por: Kalayoglu-Besisik, Sevgi, et al.
Publicado: (2012)

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
por: Zhou, Xiang, et al.
Publicado: (2020)

Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma
por: Xia, Yuan, et al.
Publicado: (2022)

An imaging review of extramedullary myeloma
por: Kay, M, et al.
Publicado: (2015)

Extramedullary disease in multiple myeloma
por: Bansal, Radhika, et al.
Publicado: (2021)

Suppression of leukocyte chemotaxis by human IgA myeloma components
Publicado: (1976)

IgA Type Multiple Myeloma, Clinical Features, and Prognosis
por: Wang, Ling, et al.
Publicado: (2018)

Neuromeningeal cryptoccocosis revealing IgA-λ multiple myeloma
por: Mtibaa, Latifa, et al.
Publicado: (2021)

Efficacy and follow‐up of humanized anti‐BCMA CAR‐T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary‐extraosseous, extramedullary‐bone related, and without extramedullary disease
por: Li, Wei, et al.
Publicado: (2022)

The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
por: San-Miguel, Jesus F., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sv05qdm1g4m4mudrtn9bbpr6rm